Emerging clinical data with nemvaleukin alfa, a novel, engineered cytokine as monotherapy and in combination with pembrolizumab in multiple tumor types

Time: 1:30 pm
day: Day Two

Details:

  • Overview of nemvaleukin’s design and mechanism of action via targeting the intermediate-affinity IL-2 receptor
  • Deep dive into our melanoma and RCC monotherapy clinical activity and next steps
  • Ovarian data in combination with pembrolizumab and how we are pursuing these clinical signals in a systematic way

Speakers: